Atrium Therapeutics, Inc. RNA NASDAQ

Atrium Therapeutics, Inc. (RNA) generated $-41.13M in operating cash flow for fiscal year 2025. After capital expenditures of $1.45M, free cash flow was $-42.57M.

Free cash flow margin was -228.7% of revenue. Cash conversion ratio was 0.83x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (50/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.83x suggests some earnings are non-cash items

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.